
|Videos|October 28, 2013
New Therapeutics in Gynecologic Cancer
Author(s)Russell J. Schilder, MD
Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.
Advertisement
Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses new therapeutics and their role in gynecologic cancers.
Clinical Pearls
- There has been a renaissance in immunology and researchers are using immunotherapies to “wake up” the immune system
- Newer therapies, such as antibodies against PD-1 and PD-L1 and enzyme inhibitors, change the microenvironment to allow the immune system to do its job and kill the cancer
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5































